v3.23.1

License Agreements - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Nov. 22, 2021 | Aug. 30, 2021 | Dec. 31, 2021 | Jan. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 21, 2021
Capitalized Contract Cost [Line Items] |  |  |  |  |  |  |  |  |  |
Royalties accrued on product sales |  |  |  |  |  | $ 400,000 | $ 200,000 |  |  |
Due to licensor |  |  |  |  |  | $ 5,757,000 |  |  | $ 5,757,000 |
Right to terminate the agreement |  |  |  |  |  | 120 days |  |  |  |
Upfront payment |  |  |  | $ 14,000,000 |  | $ 14,000,000 |  |  |  |
Total revenue |  |  |  |  | $ 14,000,000 | 5,867,000 | 2,307,000 |  |  |
Amount of certain development, regulatory, and sales milestones payments eligible to receive under license agreement |  |  |  |  |  | 257,000,000 |  |  |  |
Celgene License Agreement |  |  |  |  |  |  |  |  |  |
Capitalized Contract Cost [Line Items] |  |  |  |  |  |  |  |  |  |
Payment of license fees |  | $ 5,800,000 |  |  |  |  |  |  |  |
Related party transaction, balloon payment interest rate per annum |  | 4.00% |  |  |  |  |  |  |  |
Celgene License Agreement | EOC Pharma (Hong Kong) Limited |  |  |  |  |  |  |  |  |  |
Capitalized Contract Cost [Line Items] |  |  |  |  |  |  |  |  |  |
Payment received from license agreement |  |  |  | $ 14,000,000.0 |  |  |  |  |  |
Celgene License Agreement |  |  |  |  |  |  |  |  |  |
Capitalized Contract Cost [Line Items] |  |  |  |  |  |  |  |  |  |
Payments related to milestone |  |  |  |  |  | $ 0 | $ 0 |  |  |
License fees, percentage of previously outstanding payment obligation |  | 50.00% |  |  |  |  |  |  |  |
Due to licensor |  | $ 5,800,000 |  |  |  |  |  |  |  |
Celgene License Agreement | EOC Pharma (Hong Kong) Limited |  |  |  |  |  |  |  |  |  |
Capitalized Contract Cost [Line Items] |  |  |  |  |  |  |  |  |  |
Payments related to milestone |  |  | $ 1,000,000 |  |  |  |  |  |  |
Due to licensor |  |  |  |  |  |  |  |  |  | $ 200,000
Sublicense fees, percentage |  |  |  | 20.00% |  |  |  | 20.00% |  |
Total revenue | $ 1,000,000 |  |  |  |  |  |  |  |  |

X
- Definition Amount of certain development, regulatory, and sales milestones payments eligible to receive under license agreement. + References No definition available. + Details
Name: | aadi_AmountOfCertainDevelopmentRegulatoryAndSalesMilestonesPaymentsEligibleToReceiveUnderLicenseAgreement
Namespace Prefix: | aadi_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Due To Licensor + References No definition available. + Details
Name: | aadi_DueToLicensor
Namespace Prefix: | aadi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License Fees Including Percentage Of Outstanding Payment Obligation + References No definition available. + Details
Name: | aadi_LicenseFeesIncludingPercentageOfOutstandingPaymentObligation
Namespace Prefix: | aadi_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payment Of License Fees + References No definition available. + Details
Name: | aadi_PaymentOfLicenseFees
Namespace Prefix: | aadi_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments related to milestone. + References No definition available. + Details
Name: | aadi_PaymentsRelatedToMilestone
Namespace Prefix: | aadi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Related party transaction balloon payment interest rate per annum. + References No definition available. + Details
Name: | aadi_RelatedPartyTransactionBalloonPaymentInterestRatePerAnnum
Namespace Prefix: | aadi_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Right to terminate the license agreement. + References No definition available. + Details
Name: | aadi_RightToTerminateLicenseAgreement
Namespace Prefix: | aadi_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalties Were Accrued On Product Sales + References No definition available. + Details
Name: | aadi_RoyaltiesWereAccruedOnProductSales
Namespace Prefix: | aadi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sublicense fees percentage. + References No definition available. + Details
Name: | aadi_SublicenseFeesPercentage
Namespace Prefix: | aadi_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront Payment For License Agreement. + References No definition available. + Details
Name: | aadi_UpfrontPaymentForLicenseAgreement
Namespace Prefix: | aadi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CapitalizedContractCostLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aadi_CelgeneLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=aadi_EOCPharmaHongKongLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=aadi_CelgeneLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |